The results from a study shows stereotactic ablative radiotherapy (SABR) for renal cell carcinoma (RCC) has been proven to be as safe and effective for RCC patients with one kidney as for those with two kidneys.

This study is the result of an analysis of the largest international dataset of solitary kidney patients to be treated with SABR, and was presented at the American Society for Radiation Oncology (ASTRO) Annual Meeting in San Antonio, Texas last week.

Read more in Practice Update here